Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Revolution Medicines, Inc.
Revolution Medicines, Inc.
Eli Lilly and Company
AbbVie
Fudan University
Exelixis
Ohio State University Comprehensive Cancer Center
ImmunityBio, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
Gustave Roussy, Cancer Campus, Grand Paris
OHSU Knight Cancer Institute
Stanford University
Georgetown University
N.N. Petrov National Medical Research Center of Oncology
OHSU Knight Cancer Institute
Sumitomo Pharma America, Inc.
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Gilead Sciences
Abramson Cancer Center at Penn Medicine
TG Therapeutics, Inc.
Northwestern University
University of Pittsburgh
Leaf Vertical Inc.
University of California, San Francisco
Massachusetts General Hospital
H. Lee Moffitt Cancer Center and Research Institute
Alliance for Clinical Trials in Oncology
Royal Marsden NHS Foundation Trust
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
Ohio State University Comprehensive Cancer Center
Hoffmann-La Roche
Duke University
Hoffmann-La Roche
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Roswell Park Cancer Institute
National Cancer Institute (NCI)
University of California, San Francisco
University of California, San Francisco
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Eli Lilly and Company
Massachusetts General Hospital
University of Oklahoma